Status:

COMPLETED

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Healthy Participants

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on...

Eligibility Criteria

Inclusion

  • Women not of childbearing potential and men, ages 18 or local age of majority to 55 years, inclusive
  • Healthy male and female non-Japanese participants without clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations
  • Body mass index (BMI) of 18 to 32 kg/m2, inclusive, and total body weight ≥ 50 kg

Exclusion

  • Known or suspected autoimmune disorder, including but not limited to rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, Behcet's disease, dermatomyositis, MS, moderate to severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active autoimmune disease for which a participant requires medical follow-up or medical treatment
  • Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
  • Presence of any factors that would predispose the participant to develop infection
  • A history of bacterial or fungal meningitis within 1 year prior to screening
  • A history of intracranial or intraspinal bleeding
  • Known intracranial space-occupying mass, including meningioma
  • Other protocol-defined inclusion/exclusion criteria apply

Key Trial Info

Start Date :

May 27 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 10 2022

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT04882150

Start Date

May 27 2021

End Date

June 10 2022

Last Update

January 12 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Local Institution - 0002

Salt Lake City, Utah, United States, 84124